000058474 001__ 58474
000058474 005__ 20200221144259.0
000058474 0247_ $$2doi$$a10.1007/s12094-016-1595-9
000058474 0248_ $$2sideral$$a97570
000058474 037__ $$aART-2016-97570
000058474 041__ $$aeng
000058474 100__ $$aRivera, F.
000058474 245__ $$aMedical oncology future plan of the Spanish Society of Medical Oncology: challenges and future needs of the Spanish oncologists
000058474 260__ $$c2016
000058474 5060_ $$aAccess copy available to the general public$$fUnrestricted
000058474 5203_ $$aPurpose: The SEOM Future Plan is aimed at identifying the main challenges, trends and needs of the medical oncology speciality over the next years, including potential oncologist workforce shortages, and proposing recommendations to overcome them. Methods: The estimations of the required medical oncologists workforce are based on an updated Medical Oncologist Register in Spain, Medical Oncology Departments activity data, dedication times and projected cancer incidence. Challenges, needs and future recommendations were drawn from an opinion survey and an advisory board. Results: A shortage of 211 FTE medical oncologist specialists has been established. To maintain an optimal ratio of 158 new cases/FTE, medical oncology workforce should reach 1881 FTE by 2035. Conclusions: Main recommendations to face the growing demand and complexity of oncology services include a yearly growth of 2.5% of medical oncologist’s workforce until 2035, and development and application of more accurate quality indicators for cancer care and health outcomes measure.
000058474 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000058474 590__ $$a2.353$$b2016
000058474 591__ $$aONCOLOGY$$b141 / 217 = 0.65$$c2016$$dQ3$$eT2
000058474 592__ $$a0.774$$b2016
000058474 593__ $$aMedicine (miscellaneous)$$c2016$$dQ2
000058474 593__ $$aOncology$$c2016$$dQ2
000058474 593__ $$aCancer Research$$c2016$$dQ3
000058474 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000058474 700__ $$0(orcid)0000-0003-0123-4274$$aAndres, R.$$uUniversidad de Zaragoza
000058474 700__ $$aFelip, E.
000058474 700__ $$aGarcia-Campelo, R.
000058474 700__ $$aLianes, P.
000058474 700__ $$aLlombart, A.
000058474 700__ $$aPiera, J.M.
000058474 700__ $$aPuente, J.
000058474 700__ $$aRodriguez, C.A.
000058474 700__ $$aVera, R.
000058474 700__ $$aVirizuela, J.A.
000058474 700__ $$aMartin, M.
000058474 700__ $$aGarrido, P.
000058474 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Medicina
000058474 773__ $$g(2016), 1-11$$pClin. transl. oncol.$$tClinical and Translational Oncology$$x1699-048X
000058474 8564_ $$s565767$$uhttps://zaguan.unizar.es/record/58474/files/texto_completo.pdf$$yVersión publicada
000058474 8564_ $$s81748$$uhttps://zaguan.unizar.es/record/58474/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000058474 909CO $$ooai:zaguan.unizar.es:58474$$particulos$$pdriver
000058474 951__ $$a2020-02-21-13:31:46
000058474 980__ $$aARTICLE